Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tarsus Pharmaceuticals (TARS), Prime Medicine, Inc. ...

Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Prime Medicine, Inc. (PRME) and Ascendis Pharma (ASND)

Barclays analyst Eliana Merle maintained a Buy rating on Ascendis Pharma today and set a price target of $345.00. According to TipRanks, Merle is a...

Barclays Remains a Buy on Ascendis Pharma (ASND)

Ascendis Pharma ( ($ASND) ) has provided an update. On June 30, 2026, Ascendis Pharma reported new 104-week radiographic data from its completed pi...

Ascendis Pharma Unveils Two-Year Pivotal Trial Data for TransCon CNP in Children With Achondroplasia

The latest update is out from Ascendis Pharma ( ($ASND) ). On June 29, 2026, Ascendis Pharma A/S closed an exercise window for outstanding warrants...

Ascendis Pharma Closes Warrant Exercise Window, Expands Share Capital

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND) and Corbus Pharmaceuticals (C...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ASND	$259.80	-3.27%	485.82K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ASND	$259.80	-3.3%	485.82K
3
4
5
6

ASND

ASND

Get Ascendis Pharma A/S Data in Excel

Get Ascendis Pharma A/S Data in Excel